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Brazil faces a knowledge gap concerning the factors
associated with smoking patterns.1 In their large survey,
Opaleye et al. report that approximately 16% of the 7,921
interviewees reported daily use of cigarettes, of whom 65%
stated a wish to reduce or quit smoking.1 Varenicline, a
partial agonist of the a4b2 nicotinic acetylcholine receptor,
is considered one of the first-line treatments for tobacco
dependence, which also include nicotine replacement
therapy and bupropion.2 The efficacy of varenicline as a
smoking cessation treatment is attributable to its binding
and activation of the receptor at a significantly lower
concentration than nicotine, thus preventing nicotine
binding.3
During post-marketing surveillance studies, varenicline
use was found to be associated with neuropsychiatric
side effects, such as changes in behavior, depressed
mood, and suicidal thoughts or actions.2,3 These side
effects can occur in patients with or without preexisting
neuropsychiatric disorders.3 Since some of these effects
are related to nicotine withdrawal, it is difficult to
distinguish whether the cause is the drug or the
abstinence.4 In 2009, the Food and Drug Administration
(FDA) required manufacturers of varenicline to add a
boxed warning to its label.4 According to Rigotti,2
varenicline represents an important treatment for
tobacco dependence, but the decision to prescribe it
requires careful consideration of the risk–benefit balance
and close monitoring by clinicians. The medication
should be discontinued immediately if symptoms that
concern the clinician, caregivers, family, or patient are
observed.3
In Brazil, although varenicline is approved for sale
‘‘by prescription only,’’ it is readily available for purchase
over the counter. No data are available on the number of
side effects associated with the use of this drug in the
country. The Brazilian Health Surveillance Agency
(ANVISA) states that the release of this information was
not authorized. Moore et al. assert that varenicline use is
associated with an increased risk of suicidal/self-injury
behavior and depression in smokers attempting to quit.5
Data for this study were drawn from case reports of
adverse drug events received by the FDA from 1998 to
2010. The authors identified 3,249 cases of suicidal
behavior and depression, with varenicline accounting for
90% of reports. The increased risk associated with this
medication remained disproportionate even after com-
parison with other medications for smoking cessation,
such as bupropion and nicotine replacement therapy, and
after exclusion of case reports involving concomitant
therapy with drugs carrying boxed warnings or precau-
tions for suicidality in their prescribing information. Given
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the potential risks of varenicline, we believe that its sale in
Brazil should only happen with retention of the prescrip-
tion form. As tobacco dependence is a complex syn-
drome, it is essential that skilled health professionals help
patients in the cessation process.
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